Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:
5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,3
Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:
4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,3
*Mean baseline of 12.8 headache days of at least moderate severity per month with monthly dosing.1
†Reduction in monthly average number of headache days from the Long-Term Extension study was 6.4 with quarterly dosing.3